Anti-tumor necrosis factor (TNF) therapy is effective in inducing remission in Crohn's disease in 60% of patients. No serological biomarkers are available, which can predict response to anti-TNF. The researchers aimed to investigate serological markers of collagen turnover reflecting tissue inflammation as predictors of response to anti-TNF. In 2 retrospective observational cohorts, Four markers were measured in serum and compared with standard C-reactive protein in patients with active Crohn's disease who started therapy. The results show that the response to anti-TNF therapy within the first 14 weeks of treatment can be predicted based on baseline levels of basement membrane marker C4M. This marker could be used as a biomarker for response to anti-TNF and could aid in early therapy decision-making.
Serological biomarkers of tissue turnover identify responders to anti-TNF therapy in Crohn's disease: a pilot study
The IE from MS no longer understands current scripting languages, the latest main version (version 11) is from 2013 and has not been further developed since 2015.
Our recommendation: Use only the latest versions of modern browsers, for example Google Chrome, Mozilla Firefox or Microsofrt Edge, because only this guarantees you sufficient protection against infections and the correct display of websites!